{"id":"bf11d028863c","type":"article","url":"https://hartvaat.nl/2026/01/22/werkzaamheid-en-veiligheid-van-finerenon-bij-primair-aldosteronisme/","title":"Werkzaamheid en veiligheid van finerenon bij primair aldosteronisme","title_en":"Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Multicenter Prospective Study","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","internist"],"tags":["fidelio-dkd","fidelity","figaro-dkd","finerenon","finerenon-hartfalen-nierziekte","mra-aldosteronantagonisten","vrouwen"],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26048","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26048","authors":["Ping Li"],"significance":6,"published":"2026-01-22","source_date":"2026-01-22","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/kdigo-richtlijn-ckd-2024/"],"congress":"","summary_en":"This multicenter study provided the first prospective evidence on finerenone efficacy and safety in primary aldosteronism, testing the nonsteroidal MRA in the condition where aldosterone excess is the primary pathology.","created":"2026-07-03T10:25:31Z","updated":"2026-07-03T13:24:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Finerenon is een nieuwe niet-steroïdale mineralocorticoïdreceptorantagonist. Robuust bewijs over werkzaamheid en veiligheid bij primair aldosteronisme ontbrak. Deze prospectieve multicenter-studie onderzocht finerenon bij deze patiëntengroep.","abstract_original":"Hypertension, Volume 83, Issue 5, Page e26048, May 1, 2026. BACKGROUND:Finerenone is a novel nonsteroidal mineralocorticoid receptor antagonist. However, robust evidence about its efficacy and safety in primary aldosteronism is scarce.METHODS:In this prospective, multicenter, single-arm, and exploratory trial, we enrolled adults (aged ≤75 years) with primary aldosteronism, an office blood pressure (BP) ranging from 140 to 180/90 to 120 mm Hg, and an estimated glomerular filtration rate ≥60 mL/min per 1.73 m². Eligible patients received finerenone (20–40 mg/d) treatment for 12 weeks. The primary outcome was the change in daytime systolic BP at 12 weeks.RESULTS:Fifty-seven patients were ultimately treated. Per-protocol analysis revealed that finerenone treatment significantly reduced mean daytime systolic BP (−6.69±1.60 mm Hg;P<0.001) and diastolic BP (−4.55±1.06 mm Hg;P<0.001) according to ambulatory monitoring. Mean office BP decreased even more substantially (systolic BP"}